Portal vein embolization and application of autologous stem cells in patients with primary unresectable liver tumours

Portal vein embolization and application of autologous stem cells in patients with primary unresectable liver tumours

Only 15-20 % of patients with liver tumours can undergo radical surgery. Insufficient future liver remnant volume (FLRV) is one of the main causes of tumours unresectability. Portal vein embolization (PVE) together with administration of haematopoietic stem cells (HSC) may expand the operability of...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Bratislava Medical Journal 2013, Vol.114 (7), p.389-393
Hauptverfasser: Treska, V, Koza, V, Lysak, D, Slauf, F, Mirka, H, Sutnar, A, Skalicky, T, Fichtl, J, Ferda, J
Format: Artikel
Sprache:eng
Schlagworte:
Aged
Combined Modality Therapy
Embolization, Therapeutic
Female
Hematopoietic Stem Cell Transplantation
Humans
Liver Neoplasms - therapy
Male
Middle Aged
Pilot Projects
Portal Vein
Prospective Studies
Transplantation, Autologous
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Only 15-20 % of patients with liver tumours can undergo radical surgery. Insufficient future liver remnant volume (FLRV) is one of the main causes of tumours unresectability. Portal vein embolization (PVE) together with administration of haematopoietic stem cells (HSC) may expand the operability of primary unresectable liver tumours. In this pilot study, the authors reported on five patients (1 hepatocellular carcinoma, 4 colorectal cancer metastases) with FLRV
ISSN:0006-9248
1336-0345
1336-0345
DOI:10.4149/BLL_2013_082